Abstract 2751: Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer

Breast cancer patients who have minimal residual disease (MRD) after surgery or systemic therapies are at a higher risk of relapse. The ability of MRD to efficiently switch between quiescence and proliferation, depending upon the challenges in the body, increases likelihood of relapse. With the goal of developing therapies that would halt the progression of MRD to clinical metastases, we have developed a cell culture model of such poor prognosis...